UPCOMING: WuXi Representatives Visit Israel for EFMC-ASMC’15
Members of WuXi’s small molecule drug discovery platform (International Discovery Service Unit – IDSU) will be attending the EFMC International Symposium on Advances in Synthetic and Medicinal Chemistry from November 15-18 to meet with Israeli clients and colleagues. WuXi brings world class capability and capacity through its open access platform so that anyone and any company can discover and develop healthcare products to benefit patients.
“Our team looks forward to fostering the small molecule innovation of Israeli entrepreneurs and to helping advance the world class science found in Israel” says Richard Soll, Senior VP, IDSU.
“I look forward to catching up with current and prospective clients face-to-face, and continuing to find ways to support and build our partnerships in this exciting discovery hub” says David Madge, IDSU’s Program Director.
Please contact Dana Yarden, Executive Director of Business Development, Israel for further details on WuXi’s services and IDSU’s trip to Israel.
Prospects for U.S. and Israel Cell and Gene Therapy: An Interview with Alan Moore, Vice President of Strategic Accounts and Cell Manufacturing
The Wuxi government delegation visited Israel last week exploring ways to promote economic transformation for Wuxi city through developing advanced technologies and cultivating potential collaborations between Israel and Wuxi companies. Dana Yarden of WuXi’s Israel Office had the opportunity to present to the delegation on general economic trends in Israel and on WuXi AppTec’s activities in Israel.
Innovation That Matters
WuXi NextCODE in Bloomberg on Ending a 30-year Diagnostic Odyssey in 3 Weeks